Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV

2021 ◽  
Vol 87 (3) ◽  
pp. 978-984
Author(s):  
Grant B. Ellsworth ◽  
Elizabeth A. Stier ◽  
Elizabeth Y. Chiao ◽  
Shelly Y. Lensing ◽  
Teresa Darragh ◽  
...  
Keyword(s):  
Screening Tool ◽  
High Grade ◽  
Squamous Intraepithelial Lesions ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
Intraepithelial Lesions

scholarly journals Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV

AIDS ◽  
2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Elizabeth Chiao ◽  
Shelly Y. Lensing ◽  
Dorothy J. Wiley ◽  
Ashish A. Deshmukh ◽  
Jeannette Lee ◽  
...  
Keyword(s):  
High Grade ◽  
Squamous Intraepithelial Lesions ◽  
Women Living With Hiv ◽  
Screening Strategies ◽  
Living With Hiv ◽  
Intraepithelial Lesions

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial

2020 ◽  
Author(s):  
Cynthia Firnhaber ◽  
Avril Swarts ◽  
Vuyokazi Jezile ◽  
Masango Mulongo ◽  
Bridgette Goeieman ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
High Grade ◽  
Double Blind ◽  
Women Living With Hiv ◽  
Immunodeficiency Virus ◽  
Living With Hiv ◽  
Intraepithelial Lesions

Abstract Background Women living with human immunodeficiency virus (HIV), especially in sub-Saharan Africa, are at high risk for cervical high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. These women have high HSIL recurrence rates after loop electroexcision procedure (LEEP). Retrospective studies suggest that human papillomavirus (HPV) vaccination improves response to treatment of cervical HSIL. Methods We performed a double-blind, randomized clinical trial enrolling 180 women living with HIV in Johannesburg, South Africa, diagnosed with cervical HSIL by colposcopic biopsy. Women received quadrivalent HPV vaccine or placebo (1:1) at entry, week 4, and week 26. LEEP was performed at week 4. Colposcopic-directed biopsies and cervical cytology were performed at weeks 26 and 52. The primary endpoint, cervical HSIL by histology or cytology at either week 26 or 52, was compared between arms using χ 2 analysis. Results Participant characteristics included median age of 39 years and median CD4 count 489 cells/μL, and 94% had HIV suppression. One hundred seventy-four women completed the vaccine/placebo series and had evaluable results at week 26 or 52. The proportion experiencing the primary endpoint was similar in the vaccine and placebo groups (53% vs 45%; relative risk, 1.18 [95% confidence interval, .87–1.6]; P = .29). HSIL recurrence was associated with a LEEP biopsy result of HSIL and detection of HSIL at the margins of the LEEP sample. Conclusions This study did not support HPV vaccination to prevent recurrent HSIL after LEEP in women living with HIV. Recurrent HSIL was high despite virologic suppression. Improved treatments are needed for HSIL to reduce the burden of cervical cancer among women living with HIV.

Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4aand high-risk human papillomavirus

2007 ◽  
Vol 86 (1) ◽  
pp. 94-98 ◽  
Author(s):  
José Eleutério Jr ◽  
Paulo César Giraldo ◽  
Ana Katherine Gonçalves ◽  
Diane Isabelle Magno Cavalcante ◽  
Francisco Valdeci de Almeida Ferreira ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Prognostic Markers ◽  
High Grade ◽  
Squamous Intraepithelial Lesions ◽  
Intraepithelial Lesions
Sign in / Sign up

Export Citation Format

Share Document